When Will Retatrutide Be Available? FDA Status & Timeline

Last updated: August 2026

Retatrutide just proved it can strip nearly 29% of body weight in clinical trials — and you still can't get it. Here's exactly where it stands, when that changes, and what you can do right now while waiting.

Key Takeaways

• Retatrutide is not FDA approved. As of August 2026, it remains an investigational drug. No pharmacy — compounding or retail — can legally dispense it under a standard prescription.
• Eli Lilly has committed to a filing date, not a release date. On July 23, 2026 and again in its August 5, 2026 quarterly results, Lilly said it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. That is the submission, not the approval.
• The Phase 3 program is finished. Lilly says the clinical data package is now complete across five positive Phase 3 trials, covering obesity, type 2 diabetes, obstructive sleep apnea and knee osteoarthritis pain.
• Working backward from a Q1 2027 filing, the earliest realistic FDA decision is late 2027, and early-to-mid 2028 is the base case under a standard review clock. Pharmacy shelves come after that.
• One legitimate pre-approval route now exists. Lilly opened a physician-initiated expanded access program for a narrow group of patients with severe, refractory obesity. It is not a way to buy the drug — see below.
• The "discontinuation" rumors are false. Retatrutide was never discontinued. That confusion comes from a Phase 2 trial that simply ended (as trials do). The drug is very much alive.
• The compounded retatrutide market is not a legal gray area anymore. The FDA states plainly that retatrutide "cannot be used in compounding under federal law," and in August 2026 Lilly sued six US sellers and referred more than 200 entities to regulators. Anything sold to consumers as retatrutide today is outside the approved supply chain.
• TRIUMPH-1 delivered the biggest Phase 3 weight-loss result in pharmaceutical history — a mean 28.3% (70.3 lbs) at 80 weeks on 12 mg, with 65.3% of that group dropping below a BMI of 30. That's not a typo.
• The FDA timeline no longer depends on more trial data. It depends on Lilly's manufacturing paperwork, the filing decision, and whether the review is standard or priority.

The question everyone's asking is simple: when can I actually get this? Honestly, the answer is still frustrating. But it's clearer than it was six months ago. The Phase 3 data is rolling in, Eli Lilly has given public timeline guidance, and the regulatory path is mapped — even if it's slower than any of us want.

Let's break down exactly where retatrutide stands, when things are actually going to move, and what your options are while the FDA clock ticks.

Is Retatrutide Available Today? The Short Answer

No. As of August 2026, retatrutide is not approved by any regulator anywhere in the world, and no pharmacy — retail, mail-order or compounding — can legally fill a prescription for it. Lilly's own wording in its July 2026 trial announcement: retatrutide "is an investigational molecule that cannot be legally sold or marketed for human use."

There are exactly two routes that put real, Lilly-manufactured retatrutide into a patient's hands before approval, and both run through a physician rather than a checkout page:

1. A clinical trial. Most of the TRIUMPH program has now closed to enrollment. Per current ClinicalTrials.gov listings, the retatrutide studies still marked as recruiting are the SYNERGY-Outcomes liver-disease master protocol (NCT07165028) and a Phase 2 obesity study (NCT07467447). Trial participants may receive placebo.

2. Lilly's pre-approval expanded access program. This is new and most people waiting on retatrutide have never heard of it. Lilly registered a single-patient expanded access record (NCT07629401) on June 5, 2026; it was still listed as "Available" at its August 6, 2026 update. The published criteria are narrow, and all of them must be met:

• Age 18 or older
• BMI of 35 kg/m² or higher despite adherence to and tolerance of the highest available dose of an approved chronic weight-management therapy
• Two or more serious or life-threatening obesity-related complications currently being treated to standard of care
• Unable to join an ongoing retatrutide trial (ineligible, or no reasonably accessible site)
• All standard options, including bariatric surgery, already discussed through shared decision-making

Requests are initiated by the treating physician, not the patient. Lilly directs physicians to the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979), and says availability still depends on geography, supply and individual assessment. If you think you qualify, the action item is an appointment, not an email to Lilly.

Everything else marketed as retatrutide right now — vials labeled "research use only," medical spa protocols, telehealth "triple agonist" programs — sits outside both routes. See the legal status section below before you spend money there.

What Retatrutide Is (Quick Primer)

Retatrutide (code name LY3437943) is a triple agonist — meaning it activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. Every other approved weight-loss drug on the market hits one or two of those targets. Retatrutide hits all three.

That third target — glucagon — is the key difference. It signals the liver to burn more fat and ramps up energy expenditure in ways that semaglutide and tirzepatide simply don't. The result? Weight loss numbers that genuinely broke records in clinical testing.

For a deeper look at the mechanism, check out our what is retatrutide.

Current FDA Status: Where Things Stand in August 2026

Retatrutide has finished the Phase 3 trials that matter for a first approval. Nothing has been submitted to the FDA yet — the application itself is the next step, and Lilly has put a date on it.

Here's what's happened:

• February 2026: In its Q4 2025 results, Lilly described TRIUMPH-4 (obesity plus knee osteoarthritis) as retatrutide's first successful Phase 3 trial, with weight loss of up to an average of 71.2 lbs alongside relief from osteoarthritis pain.
• May–June 2026: TRIUMPH-1, the pivotal obesity trial, reported. Full results were presented at the American Diabetes Association's 86th Scientific Sessions on June 6, 2026, together with TRANSCEND-T2D-1 in type 2 diabetes, which was published simultaneously in The Lancet.
• July 23, 2026: TRIUMPH-2 (obesity plus type 2 diabetes) and TRIUMPH-3 (severe obesity plus established cardiovascular disease) both hit their primary endpoints. Lilly said it was completing the Chemistry, Manufacturing and Controls package and plans "to subsequently submit retatrutide in Q1 2027 for U.S. approval."
• August 5, 2026: Lilly's Q2 2026 results repeated it in regulatory language: the clinical data package "is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027."
• Still running: the long-horizon outcome studies — TRIUMPH-Outcomes (NCT06383390, 10,000 participants, cardiovascular and kidney events, primary completion 2029) and the SYNERGY-Outcomes MASH program. Those are label-expansion trials, not gating items for a first approval.

So the honest summary as of August 2026: the science is done, the paperwork is not, and the submission target is Q1 2027.

The TRIUMPH Phase 3 Program: What's Still In Progress

The TRIUMPH program is enormous. It's not one trial — it's a constellation of them covering different patient populations. Before Lilly files the NDA, they need pivotal data from multiple arms.

Statuses above are from the ClinicalTrials.gov registry records for each study.

TRIUMPH-1 was the big one — the broad obesity pivotal trial the FDA will primarily lean on for an obesity indication. It has now read out. With TRIUMPH-2 and TRIUMPH-3 following in July 2026, Lilly's stated position is that the efficacy and safety package is complete and the remaining work is manufacturing documentation and the submission itself.

Retatrutide Release Date: When You Can Actually Get It

The retatrutide release date has not been announced, and it cannot be until the FDA approves the drug. What Eli Lilly has announced is a submission date: Q1 2027. Everything credible about a release date is arithmetic run forward from that. Lilly typically confirms launch timing only after approval is granted, which historically means an announcement landing 0–3 months ahead of pharmacy availability.

Here is what we know about the retatrutide release date as of August 2026:

Best Case Retatrutide Release Date: Late 2027

This scenario requires three things to break in sequence:

1. Lilly submits early in Q1 2027, as guided
2. The FDA accepts the application for filing — the agency takes up to 60 days to decide that
3. The FDA grants Priority Review — under the current PDUFA goals, a priority original BLA is acted on within 6 months of the 60-day filing date, versus 10 months for a standard review

A January 2027 submission accepted for filing in March 2027, on a priority clock, points to an FDA decision around September–November 2027, with launch inside the following quarter. This is the aggressive timeline. Possible, not promised — priority review is a designation the FDA grants, not something a sponsor can schedule.

Likely Retatrutide Release Date: 2028

This is what the standard review clock produces, and it is the sensible default:

1. BLA submitted in Q1 2027
2. Filing decision within 60 days, so roughly Q2 2027
3. Standard 10-month review from that filing date
4. FDA decision in the first half of 2028
5. Commercial launch within 0–3 months of approval

That puts the actual retatrutide release date — the point at which a prescription can be filled at a pharmacy — in 2028 for most people, even with everything going right.

Worst Case Retatrutide Release Date: Late 2028 or Beyond

Possible delays that push the retatrutide release date further out:

• Slippage in the submission itself; the Chemistry, Manufacturing and Controls package is the piece Lilly flagged as still in progress in July 2026
• A refuse-to-file or a major amendment during review, either of which restarts or extends the clock
• An FDA Complete Response Letter requesting additional data
• Manufacturing capacity constraints — Lilly has been supply-limited on Zepbound before
• Scrutiny of the dysesthesia signal seen across the TRIUMPH trials

Note what is not on that list anymore: waiting for efficacy data. That risk retired in July 2026.

Retatrutide Release Date by Country

The US retatrutide release date will almost certainly come first. International release dates typically lag the US approval by 6–18 months as EMA, Health Canada, MHRA, TGA, and other regulators conduct their own reviews. If the US gets retatrutide in late 2027, expect:

• EU release date: Mid-to-late 2028
• UK release date: Late 2028
• Canada release date: 2028
• Australia release date: Late 2028 or 2029
• Other markets: 2029+

What Eli Lilly Has Actually Said About the Retatrutide Release Date

Searches for an "Eli Lilly retatrutide release date" or a "retatrutide launch date" turn up a lot of numbers that nobody at Lilly ever said. Here is the company's own public record, in order, with what each statement does and does not commit to:

Two details in that last line are worth pulling out.

It's a BLA, not an NDA. Most coverage still calls the coming filing a New Drug Application. Lilly calls it a Biologics License Application. For a patient counting months, the practical difference is nil: under the current PDUFA performance goals, the FDA aims to act on 90% of standard original BLA submissions within 10 months of the 60-day filing date, and on priority submissions within 6 months of that date — the same clock an NME new drug application gets.

Q1 2027 is a submission, not an approval. No regulator has an application in hand today. Any page quoting a specific retatrutide launch day, a "release date" in 2026, or a pre-order is either guessing or selling something.

Retatrutide FDA Approval Timeline: The Realistic Roadmap

Here's how the regulatory pathway looks from today:

Q1 2027 — BLA Submission Lilly's stated plan. The efficacy and safety data is complete; the gating item the company named in July 2026 was the Chemistry, Manufacturing and Controls package that accompanies the application.

Q2 2027 — FDA Filing Decision The FDA takes up to 60 days to accept or refuse the application for filing. Acceptance starts the review clock, and the goal date is measured from that 60-day filing date, not from the day the box arrives.

Q3 2027 — Review Designation Plays Out Under PDUFA goals, priority review means a decision within 6 months of the filing date; standard review means 10 months. Given the magnitude of the TRIUMPH-1 result, priority review is plausible — but not guaranteed. The dysesthesia signal (reported in 12.5% of TRIUMPH-1 participants on 12 mg versus 0.9% on placebo) is the kind of finding that draws review attention.

Late 2027 (Optimistic) to Mid-2028 (Base Case) Priority review on a January 2027 submission lands an approval decision in late 2027. A standard clock on a March 2027 submission lands in the first half of 2028. Commercial launch follows approval by 0–3 months.

Late 2028+ (Delayed Scenario) A Complete Response Letter, a major amendment during review, or manufacturing issues would push it out. Additional cardiovascular outcomes data from TRIUMPH-Outcomes doesn't gate the first approval — that trial doesn't complete until 2029.

Comparing Retatrutide to Current Options

The gap between retatrutide and everything currently available isn't marginal — it's massive. That's why patience is actually worth it here.

Let's Address the "Retatrutide Discontinuation" Confusion Directly

You've probably seen headlines or forum posts claiming retatrutide was "discontinued" or "cancelled." This is completely wrong, and here's where it came from.

Back when Phase 2 trials wrapped up, several clinical trial listings moved to "completed" status. Non-experts (and bad journalists) misread this as the program being killed. It wasn't. Phase 2 ending is a normal milestone — it's literally what's supposed to happen before Phase 3 starts.

Retatrutide has not been discontinued. Eli Lilly has continued investing billions into the TRIUMPH Phase 3 program, and 2026 has been the year it paid off: four pivotal readouts and a completed data package. Lilly's chair and CEO named retatrutide by name in the August 5, 2026 quarterly results as the company's "next-generation weight-loss medicine," alongside the Q1 2027 submission plan. A program being taken to the FDA is the opposite of a program being cancelled.

If you're seeing "discontinued" anywhere — ignore it.

Is Retatrutide Available in the USA Right Now?

Officially? No. Practically? Sort of — depending on how you define "available."

Through standard medical channels — your doctor writing a prescription, a pharmacy filling it — retatrutide is not available anywhere in the United States. This is unambiguous.

What does exist:

1. Clinical Trials If you qualify (BMI ≥30, or ≥27 with a weight-related condition, age 18+, no recent use of other weight loss meds), you can enroll. You'd get pharmaceutical-grade retatrutide at no cost, with full medical supervision. The catch: you might receive placebo, and sites are increasingly filled as enrollment closes.

Check ClinicalTrials.gov for currently enrolling sites near you.

2. Compounded Retatrutide via Peptide Suppliers This is where it gets real. A segment of the peptide market sells retatrutide — sometimes labeled as "R-30" or similar — for self-administration. Quality varies enormously between suppliers. This is not the same as FDA-approved pharmaceutical-grade product.

3. Offshore or Gray Market Some international suppliers ship to the US. Customs enforcement varies. Risk is substantially higher.

What Changed in 2026: The Legal Status Is No Longer Ambiguous

This page used to describe the peptide route as a gray area. That description has not survived 2026, and you should make your decision with the current facts:

• The FDA's position. In its guidance on unapproved GLP-1 drugs, the agency states that "retatrutide and cagrilintide cannot be used in compounding under federal law," and that these substances "are not components of FDA-approved drugs and have not been found safe and effective for any condition." The FDA says it has warned telehealth companies marketing retatrutide, API distributors selling it to compounders, and outsourcing facilities repackaging it. (FDA)
• Lilly's enforcement. On August 12, 2026, Lilly announced six new lawsuits against US sellers — compounding pharmacies, medical spas and online peptide sellers — and said it had referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general and licensing boards, and reported more than 14,000 listings across 100+ countries. Lilly's chief medical officer on what's being sold: "it is entirely unverified, unapproved and not worth the risk."
• What that means practically. There is no third-party COA, vendor reputation or shipping guarantee that converts an unapproved investigational molecule into a legal medicine. Sellers using the phrase "research use only" while shipping to consumers are exactly the conduct in Lilly's complaints.

None of this is a claim about any particular vendor's product quality. It's the regulatory reality that now sits behind every purchase in this category, and it is also why the compounding market for retatrutide is unlikely to survive approval — see the section below.

The most reliable source we've found for third-party tested compounded retatrutide is Synthro Lab — they offer certificates of analysis, competitive pricing, and fast US shipping.

For a full breakdown of sourcing options, read our where to buy retatrutide.

How Retatrutide Compares to Semaglutide: Worth the Wait?

If you're currently on Wegovy (semaglutide) or considering it, you're probably wondering whether to hold out for retatrutide instead.

Blunt take: for most people, starting something now makes more sense than waiting 18+ months. Semaglutide and tirzepatide are genuinely effective. You can lose significant weight while the FDA finishes its review.

That said — if you're already at your goal or close, or if GLP-1 monotherapy hasn't delivered the results you wanted, retatrutide may be worth the patience.

Read our full retatrutide vs semaglutide comparison for a detailed breakdown of efficacy, side effects, and who each drug is best for.

What Happens After FDA Approval

Even after approval, retatrutide won't appear on pharmacy shelves overnight.

Manufacturing ramp-up: Lilly will need months to produce commercial-scale supply. Ozempic and Wegovy faced years of shortages after approval. Retatrutide demand will be enormous.

Insurance coverage: If approved for obesity only, expect inconsistent coverage. Many plans still exclude weight management drugs. If it gets a diabetes indication too (TRANSCEND data permitting), coverage will be much broader.

Price: Expect pricing in the $1,000–$1,400/month range without insurance, similar to Zepbound and Wegovy. Lilly's pricing strategy will significantly affect accessibility.

Compounding status: Once retatrutide is FDA-approved and commercially available, it will likely be removed from compounding pharmacy access (the same thing happened with semaglutide when shortages ended). The peptide market will shrink dramatically.

If you want access to retatrutide now — before approval, before the rules change — Synthro Lab is your best current option.

Global Availability: When Will Other Countries Get It?

The FDA moves first. Then everyone else follows:

UK residents get a bit of a shortcut through MHRA's parallel review process. EU and Australia will likely wait a bit longer. In all cases, reimbursement/coverage approvals add additional months to practical access.

FAQs: Retatrutide Availability

Is retatrutide FDA approved? No. As of August 2026, retatrutide (LY3437943) has not received FDA approval for any indication, and no application is under review — Lilly says it plans to submit a Biologics License Application in Q1 2027. The Phase 3 TRIUMPH trials that support that submission have finished and reported.

When will retatrutide be available? The most realistic timeline is an FDA decision in late 2027 at the earliest and 2028 as the base case, working forward from Lilly's stated Q1 2027 BLA submission, the FDA's 60-day filing window, and a 6-month (priority) or 10-month (standard) review clock. A full commercial launch with widespread pharmacy availability would follow 0–3 months after approval.

Was retatrutide discontinued? No. This is a persistent myth. Phase 2 trials completed — which is normal — and some trial registrations show "completed" status. Eli Lilly never cancelled the retatrutide program. Five Phase 3 trials have now reported positive results, and Lilly is preparing an FDA submission for Q1 2027.

Can I get retatrutide now? Through Lilly's own channels: clinical trial enrollment if you qualify, or physician-initiated expanded access if you meet the narrow severe-obesity criteria. Outside those, the peptide/compounding market sells material labelled retatrutide from suppliers like Synthro Lab — with the legal status described above, and with the FDA stating retatrutide cannot lawfully be compounded. For a full breakdown of how to get retatrutide through current available channels, that guide covers the options in detail. Neither is the same as an FDA-approved prescription.

How much will retatrutide cost? Pricing hasn't been announced. Based on comparable GLP-1 drugs at launch, expect $1,000–$1,400/month without insurance. With a diabetes indication, insurance coverage may be more consistent than for obesity-only approval.

What dose will be available? The Phase 3 TRIUMPH trials tested 4 mg, 9 mg and 12 mg once-weekly maintenance doses, reached by stepping up from 2 mg every four weeks. In TRIUMPH-1 the three arms averaged 19.0%, 25.9% and 28.3% weight loss at 80 weeks. The commercial formulation will likely include multiple titration steps, similar to Zepbound's dosing ladder — but the approved doses are the FDA's call, not Lilly's, and nothing is settled until a label exists.

Will retatrutide replace tirzepatide? Probably not immediately. Tirzepatide (Zepbound/Mounjaro) will remain the standard of care until retatrutide reaches wide availability. Plenty of people will achieve their goals with tirzepatide before retatrutide ever hits pharmacy shelves.

Has Eli Lilly announced a retatrutide launch date? No. Lilly has never published a retatrutide launch date or release date, and it cannot until the FDA approves the drug. What Lilly has announced — in its July 23, 2026 trial announcement and again in its August 5, 2026 quarterly results — is that it plans to submit a Biologics License Application to the FDA in Q1 2027. Working forward from that submission through the FDA's review clock, a US launch in 2028 is the base case, with late 2027 possible only if the filing is early and gets priority review.

Is retatrutide available today? Not as an approved medicine, no — not in the US and not anywhere else, as of August 2026. The two legitimate pre-approval routes are enrollment in a clinical trial and Lilly's physician-initiated expanded access program for a narrow group of patients with severe, refractory obesity. Both require a doctor. Products sold directly to consumers as retatrutide are not part of either route.

Can I get retatrutide through expanded access before it's approved? Only if you meet all of Lilly's published criteria and your physician makes the request. Per the program's ClinicalTrials.gov record (NCT07629401), a candidate must be 18 or older, have a BMI of 35 or higher despite adherence to the highest available dose of an approved weight-management therapy, have two or more serious or life-threatening obesity-related complications already being treated, be unable to join a retatrutide trial, and have discussed all standard options including bariatric surgery. Physicians contact the Lilly Answers Center at 1-800-545-5979; patients cannot apply directly, and availability still depends on geography and supply.

Is retatrutide available in Canada or the UK? No — not through standard medical channels. Both countries are awaiting FDA approval, after which Health Canada and MHRA would conduct their own reviews. Clinical trial sites exist in both countries.

The Bottom Line

Retatrutide is coming. The data is extraordinary, and as of 2026 it is finished. The timeline is painful but now unusually clear for a drug this far from a pharmacy: BLA submission in Q1 2027, FDA decision in late 2027 at the earliest, 2028 as the base case for actually filling a prescription.

Between now and then, the routes that involve Lilly's own product are clinical trial enrollment and, for a narrow group of patients with severe refractory obesity, physician-initiated expanded access. If you're serious about accessing retatrutide before approval, Synthro Lab is the vendor we'd point you toward — third-party tested, US-based, and with a track record in the GLP-1 peptide space.

Don't let the wait discourage you from acting now. If you need help, current options (tirzepatide, semaglutide) are genuinely effective while you watch the TRIUMPH data roll in.

Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not approved by the FDA. Nothing on this page constitutes medical advice. Consult a licensed healthcare provider before starting any weight-loss treatment. Peptide suppliers mentioned operate in a regulatory gray area; use at your own risk.